Wednesday, September 24, 2014
4:00 pm – 5:30 pm

The Study at Yale
1157 Chapel Street
New Haven, CT 06510

As a chemistry service focused company, Cheminpharma LLC applies a non-traditional business model of using revenues generated from their business to fund novel preclinical candidates. Allomek Therapeutics, a spin-off company from Cheminpharma, was established to focus on developing CIP-137401, a novel macrocyclic inhibitor that has the potential to be a lead candidate for the orphan disease LMNA, mutated cardiomyopathy, and a variety of cancers arising from mutations in the Ras pathway.

Uday Khire, Founder and CEO of Cheminparma LLC and Cofounder of Allomek Therapeutics, will share his experience managing two very different business operations.